γδ T Cell Therapy Development for Non-Small Cell Lung Carcinoma

As a well-established company in the bio-industry, Creative Biolabs offers quality gamma delta (γδ) T cell therapy development services for research. Theγδ T cell therapy is guaranteed to perform within the specified time frame and its quality is always maintains to the end. Our laboratory services have many advanced chemical and biological technologies to satisfy customer’s needs in the fast-growing T cell therapy research.

Introduction to Non-Small Cell Lung Carcinoma

Non-small cell lung cancer (NSCLC) is the main type (85%) of lung cancer that is associated with the uncontrolled growth of healthy lung cells. NSCLC can be caused by constant smoking and long-term exposure to chemicals. NSCLC has been divided into three common subtypes: adenocarcinomas, squamous cell carcinomas, and large cell undifferentiated carcinomas. The symptoms of NSCLC include cough, headache, bone pain, vomiting, weakness, or fatigue. Surgery, medication, chemotherapy, and radiation therapy have been considered as the standard methods for NSCLC treatment.

Recently, a variety of novel strategies based on specific tumor genotypes or phenotypes have been widely generated for enhancing antitumor efficacy in clinical applications. For example, several immune checkpoint inhibitors and T-cell modulating agents targeting programmed death 1 (PD-1), epidermal growth factor receptor (EGFR), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), have been broadly used for treating patients with NSCLC. Furthermore, recent studies have revealed that γδ T cell immunotherapy represents one promising approach to NSCLC treatment both in preclinical and clinical studies.

Fig.1 Tumor cell ligands recognized by human γδ T cells. (Kakimi, 2014)

γδ T Cell for NSCLC Treatment

γδ T cells is a rare type of T cells that express γδ T cell receptor (TCR). γδ T cell plays a critical role in regulating immune responses, tumor surveillance, and homeostasis. The surface expression of NKG2D in γδ T cell can produce many kinds of cytokines, chemokines, or transcription factors, such as RANTES, interleukin-10 (IL-10), or IL-17, used in the adaptive immune system. Meanwhile, pilot studies have indicated that the recognition of various kinds of tumors, especially for NSCLC, depends on Vγ9Vδ2 T cells.

Moreover, a wide array of the ligands for Vγ9Vδ2 TCR and their metabolites, including isopentenyl pyrophosphate (IPP), isomer dimethylallyl pyrophosphate (DMAPP), and ApppI, have been considered as natural activators of Vγ9Vδ2 T cells. Besides, recent researchers have suggested that a range of NSCLC-associated molecules, like MICA and MICB, can also be recognized by using NKG2D receptors of γδ T cells without MHC restriction. Therefore, γδ T cells have shown a great prospect in cancer immunotherapy against NSCLC.

Fig.2 Strategies for γδ T cell-based immunotherapy. (Kakimi, 2014)

γδ T Cell Therapy Services for NSCLC Treatment

With the commitment of being your best γδ T cell therapy discovery partner, Creative Biolabs has established the utmost efficient integrated solutions to innovate and accelerate your development process for various tumors or cancers. Equipped with a team of professional scientists, we have established a panel of γδ T cell-based assays for our clients to study the function of γδ T cells, to design a new class of γδ T cell therapy, as well as to evaluate the safety and toxicity of γδ T cell therapy. Currently, our strategies for the generation of γδ T cell-based immunotherapy consist of two main types: one is based on the adoptive cell transfer of ex vivo expanded γδ T cells, and another is designed by using phosphoantigens for in vivo activation of γδ T cells.

In our labs, the activated γδ T cells have been used for killing many NSCLC subtypes in different murine xenotransplant tumor models. The results have illustrated that the γδ T cells and especially the Vγ9Vδ2 T cell subset, can increase antitumor property and achieve enough immune responses during NSCLC therapy. Also, our novel γδ T cell therapies can overcome many issues in current methods for treating NSCLC, such as antibodies, chimeric antigen receptor t-cell immunotherapy, and immune checkpoint inhibitors. Nowadays, we are dedicated to translating our brilliant work in the field of γδ T cell-based studies to fulfill the promise of new γδ T cell therapy for patients with NSCLC.

Creative Biolabs has an entrepreneurial team of highly-skilled and qualified experts in γδ T cell therapy development. The members have originated from a rich academic research background, bringing their experience into translation. We are very proud of providing high-quality, omnidirectional γδ T cell-based services targeting various tumor types to our valued clients to remove the difficulties of your projects. If you are interested in our services, please contact us for more details.

Reference

1. Kakimi, K., et al. Bacteroides: γδ T cell therapy for the treatment of non-small cell lung cancer. Translational lung cancer research. 2014, 3(1): 23.